Tissue-agnostic cancer therapies: promise, reality, and the path forward
Vivek Subbiah
Abstract
Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite nine FDA approvals, real-world implementation challenges persist. Progress depends on universal genomic testing, an oncogenomic-savvy workforce, innovative trials, updated regulations, and real-world evidence to maximize potential.
Topics & Concepts
CancerPath (computing)Computer scienceMedicineComputational biologyData scienceBioinformaticsIntensive care medicineBiologyInternal medicineProgramming languageCancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesCAR-T cell therapy research